These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 16533874)

  • 1. Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer.
    Weinfurt KP; Anstrom KJ; Castel LD; Schulman KA; Saad F
    Ann Oncol; 2006 Jun; 17(6):986-9. PubMed ID: 16533874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.
    Himelstein AL; Foster JC; Khatcheressian JL; Roberts JD; Seisler DK; Novotny PJ; Qin R; Go RS; Grubbs SS; O'Connor T; Velasco MR; Weckstein D; O'Mara A; Loprinzi CL; Shapiro CL
    JAMA; 2017 Jan; 317(1):48-58. PubMed ID: 28030702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
    Saad F; Gleason DM; Murray R; Tchekmedyian S; Venner P; Lacombe L; Chin JL; Vinholes JJ; Goas JA; Chen B;
    J Natl Cancer Inst; 2002 Oct; 94(19):1458-68. PubMed ID: 12359855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effectiveness and tolerability of zoledronic acid in the treatment of metastatic prostate cancer].
    Cózar Olmo JM; Carballido Rodriguez J; Luque Galvez P; Tabernero Gómez AG; Barreiro Mouro A; Sánchez Sánchez E; González Enguita C; Alcover García J; Garcia-Galisteo E; Abascal García JM; Sanchez Chapado M; GómezVeiga F; Minguez Martínez RJ; Rodriguez Antolin A; Medina López RA; Rico Morales M; Regadera Sejas FJ; Búcar Terrades S; Jamardo Gonzalez D; Gálvez R
    Actas Urol Esp; 2008 May; 32(5):492-501. PubMed ID: 18604999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective, multicenter, open-label trial of zoledronic acid in patients with hormone refractory prostate cancer.
    Hong SJ; Cho KS; Cho HY; Ahn H; Kim CS; Chung BH
    Yonsei Med J; 2007 Dec; 48(6):1001-8. PubMed ID: 18159593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer.
    Saad F
    Clin Prostate Cancer; 2005 Jun; 4(1):31-7. PubMed ID: 15992459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zoledronic Acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer.
    Saad F; Eastham J
    Urology; 2010 Nov; 76(5):1175-81. PubMed ID: 21056263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases.
    Saad F; Chen YM; Gleason DM; Chin J
    Clin Genitourin Cancer; 2007 Sep; 5(6):390-6. PubMed ID: 17956712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid.
    Vadhan-Raj S; von Moos R; Fallowfield LJ; Patrick DL; Goldwasser F; Cleeland CS; Henry DH; Novello S; Hungria V; Qian Y; Feng A; Yeh H; Chung K
    Ann Oncol; 2012 Dec; 23(12):3045-3051. PubMed ID: 22851406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Use of zoledronic acid in patients with prostate cancer bone metastases: control of pain and musculoskeletal complications].
    Paparella S; Finkelberg E; Varisco D; Tondelli E; Rocco F
    Urologia; 2011; 78(4):300-4. PubMed ID: 22139807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.
    Saad F; Gleason DM; Murray R; Tchekmedyian S; Venner P; Lacombe L; Chin JL; Vinholes JJ; Goas JA; Zheng M;
    J Natl Cancer Inst; 2004 Jun; 96(11):879-82. PubMed ID: 15173273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: the ZABTON-PC (zoledronic acid/androgen blockade trial on prostate cancer) study.
    Ueno S; Mizokami A; Fukagai T; Fujimoto N; Oh-Oka H; Kondo Y; Arai G; Ide H; Horie S; Ueki O; Kawaguchi K; Shimamura M; Orito M; Ishida T; Ikeda D; Namiki M
    Anticancer Res; 2013 Sep; 33(9):3837-44. PubMed ID: 24023317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreases in pain at rest and movement-related pain during zoledronic acid treatment in patients with bone metastases due to breast or prostate cancer: a pilot study.
    Ripamonti C; Fagnoni E; Campa T; Giardina V; Brunelli C; Pigni A; De Conno F
    Support Care Cancer; 2007 Oct; 15(10):1177-84. PubMed ID: 17333295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial.
    Amadori D; Aglietta M; Alessi B; Gianni L; Ibrahim T; Farina G; Gaion F; Bertoldo F; Santini D; Rondena R; Bogani P; Ripamonti CI
    Lancet Oncol; 2013 Jun; 14(7):663-70. PubMed ID: 23684411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.
    Cartenì G; Bordonaro R; Giotta F; Lorusso V; Scalone S; Vinaccia V; Rondena R; Amadori D
    Oncologist; 2006; 11(7):841-8. PubMed ID: 16880243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade.
    Kamiya N; Suzuki H; Endo T; Takano M; Yano M; Naoi M; Nishimi D; Kawamura K; Imamoto T; Ichikawa T
    Int J Urol; 2012 Feb; 19(2):169-73. PubMed ID: 22126137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration.
    Wardley A; Davidson N; Barrett-Lee P; Hong A; Mansi J; Dodwell D; Murphy R; Mason T; Cameron D
    Br J Cancer; 2005 May; 92(10):1869-76. PubMed ID: 15870721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
    James N; Pirrie S; Pope A; Barton D; Andronis L; Goranitis I; Collins S; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Russell M; Billingham L
    Health Technol Assess; 2016 Jul; 20(53):1-288. PubMed ID: 27434595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy.
    Israeli RS; Rosenberg SJ; Saltzstein DR; Gottesman JE; Goldstein HR; Hull GW; Tran DN; Warsi GM; Lacerna LV
    Clin Genitourin Cancer; 2007 Mar; 5(4):271-7. PubMed ID: 17553207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone.
    Saad F
    Clin Prostate Cancer; 2002 Dec; 1(3):145-52. PubMed ID: 15046689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.